RecruitingSleepAlzheimer Disease
Sleep Trial to Prevent Alzheimer's Disease
Eligible age
65+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Sponsor: Washington University School of Medicine
You may qualify if…
- ✓ Male or female.
- ✓ Any race or ethnicity.
- ✓ Participants must be age ≥65 years and able to sign informed consent.
- ✓ Global Clinical Dementia Rating (CDR) 0.
- ✓ Willing and able to undergo study procedures.
You may not qualify if…
- ✕ History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia
- ✕ STOP-Bang score \>6 for participants without PAP
- ✕ Untreated OSA with AHI ≥15 on home sleep test
- ✕ Treated sleep apnea with PAP non-compliance
- ✕ PAP compliance is defined as \>= 4 hours per night \>70% of the nights
- ✕ Plasma A-beta and tau test with a plasma p-tau 217% ≤ 1.19
- ✕ Stroke.
- ✕ Chronic kidney disease defined as patients with markers of kidney damage or eGFR of \< 45 ml/min/1.73m2.
Where it's recruiting
Missouri
St Louis
Source: ClinicalTrials.gov · NCT04629547 · last updated 2026-06-15